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New data from the BENEFIT study demonstrate that belatacept improves long-term allograft 
and patient survival after kidney transplantation, despite higher rates of biopsy-proven 
acute rejection than with ciclosporin. The noninferiority design of BENEFIT represents a 
feasible strategy to further the development of innovator drugs to reduce late graft loss. 
 
Refers to: Vincenti, F. et al. Belatacept and long-term outcomes in kidney transplantation. N. 
Engl. J. Med. 374, 333–343 (2016). 
 
In January 2016 history was made in the field of transplantation — Vincenti et al. 
demonstrated that belatacept improves long-term outcomes in kidney transplant 
recipients1. Belatacept is the first new immunosuppressive compound that has been shown 
in a phase III trial to improve patient and graft survival since ciclosporin was approved for 
the prevention of kidney transplant rejection in 1983.  
 
In their follow-up analysis of the BENEFIT study, Vincenti et al. found that recipient mortality 
at 7 years after transplantation was significantly lower with the combination of belatacept 
plus basiliximab induction, mycophenolate mofetil and glucocorticoids, than with ciclosporin 
plus the additional agents1. The rate of graft failure 7 years after transplantation was also 
lower among those patients who received the belatacept-based regimen, although this 
trend did not reach statistical significance. 
 
Short-term renal allograft recipient and graft survival are now excellent, but outcomes are 
less favourable in the long term. Transplant kidneys fail, and patients die at a constant rate, 
with only modest improvement since the 1980s2. This long-term loss of kidney grafts and 
patient mortality is explained by a spectrum of pathologies and progressive diseases, 
including graft rejection, chronic transplant injury, drug nephrotoxicity, cardiovascular 
disease, infections and cancer. 
 
The wide spectrum of mechanisms of graft loss indicate that it is a misconception to think 
that targeting one aspect — such as graft rejection or patient mortality — at the expense of 
others will lead to improved outcomes. For instance, increasing global immunosuppression 
reduces the risk of acute rejection, but could lead to worse patient outcomes in the long 
term as a result of an increased risk of infections or cancer. Novel therapies or innovative 
combination strategies are necessary to achieve powerful immunosuppression whilst 
avoiding the risks associated with over-immunosuppression. 
 
Almost 5 years ago, in June 2011, the EMA and FDA approved the less-intensive belatacept 
dosing regimen, based on the results of two phase III trials: BENEFIT3, which enrolled 
recipients of standard-criteria-donor kidneys, and BENEFIT-EXT4, which enrolled recipients of 
extended-criteria-donor kidneys. Three key reasons exist for enthusiasm about the use of 
belatacept as a baseline immunosuppressant in kidney transplantation. First, this agent has 
unique immunosuppressive characteristics. Despite an increased risk of early acute 
rejection, the long-term data from the BENEFIT study illustrate that belatacept decreases 
the risk of development of de novo donor-specific HLA antibodies in comparison with 
ciclosporin1. Moreover, the prevention of donor-specific antibody (DSA) formation with 
belatacept seems to be a dose-dependent effect. Given the great impact of antibody-
mediated rejection (ABMR) on kidney graft outcome, and the decreased relevance of 
reversible T-cell mediated rejection5, this property of belatacept is a very welcome 
characteristic with great clinical potential. 
 
Second, in addition to the unique immunosuppressive properties of belatacept, non-immune 
effects of this agent were noted in the BENEFIT study6. Ciclosporin and other currently used 
immunosuppressants (tacrolimus, sirolimus, and everolimus) are associated with very 
undesirable metabolic adverse effects, including hypertension, hyperlipidaemia and diabetes 
mellitus7. In BENEFIT, the belatacept-treated patients showed significantly better control of 
these important cardiovascular risk factors than did the ciclosporin-treated patients 6, which 
ultimately translated into a numerically decreased risk of death from cardiovascular causes 
at 7 years (2.7% in the less-intensive and the more-intensive belatacept groups compared 
with 5.0% in the ciclosporin group)1, although the number of events was too low to enable 
robust statistical evaluation. 
 
The third reason for enthusiasm about belatacept is the finding that in the less-intensive 
treatment group, the percentage of non-cardiovascular deaths was lower than in the 
ciclosporin group (3.1% versus 6.3%, respectively)1. Again, the small number of events does 
not enable further evaluation of the specific causes of this numerically lower risk. We 
conclude that the very welcome immunosuppressive characteristics of belatacept do not 
translate into an increased risk of overall infection-related or cancer-related mortality, at 
least not in this 7-year time frame. These results were obtained despite enrollment of 
transplant recipients who were Epstein–Barr virus (EBV)-negative at baseline. EBV-negative 
patients have an increased risk of developing post-transplant lymphoproliferative disease 
when treated with belatacept compared with ciclosporin1, so are currently excluded from 
the EMA and FDA market authorization of belatacept. 
 
In addition to enthusiasm about belatacept as an immunosuppressive agent in kidney 
transplantation, the design of the phase III studies used for marketing authorization of this 
agent8, and more importantly the long-term follow-up data1 warrant discussion. Marketing 
authorization for belatacept was achieved using noninferiority studies for classic end points 
in kidney transplantation (that is, biopsy-proven acute rejection, graft survival and patient 
survival) and superiority for measured glomerular filtration rate (GFR). This noninferiority 
trial design is in sharp contrast to the design of the phase III studies of all previously 
approved immunosuppressants in kidney transplantation, which used superiority in patient 
and graft survival (azathioprine and ciclosporin), or more recently in the rate of biopsy-
proven acute rejection without survival improvement (Table 1). Belatacept was thus 
approved despite a 17% incidence of biopsy-proven acute rejection at 1 year in the less-
intense belatacept group, compared to a 7% incidence in the ciclosporin group3. 
 
In hindsight, the radically different study design, and the definition of the noninferiority 
margin for biopsy-proven acute rejection (a 20% higher incidence of acute rejection with 
belatacept compared to ciclosporin was considered noninferior) 8 were crucial for the 
approval of belatacept. The new data by Vincenti and colleagues show that the increased 
risk of acute rejection with belatacept compared to ciclosporin did not translate into worse 
long-term graft outcomes1. On the contrary, the ciclosporin group had the lowest risk of 
unspecified acute rejection but experienced the worst long-term outcomes. 
 
The uncoupling of unspecified acute rejection from the risk of graft failure in the BENEFIT 
study is unique in the history of novel drugs approved for kidney transplantation, and 
illustrates that unspecified acute rejection should no longer be considered the primary end 
point as it was in the early days of transplantation when acute cellular rejection was the 
main determinant of graft failure9. Based on the long-term BENEFIT data, two interesting 
alternative surrogate markers for late graft loss can be proposed: GFR at 1 year or GFR 
evolution, and the development of de novo DSAs. In the BENEFIT study, however, a lower 
risk of donor-specific HLA antibody formation and improved graft function with belatacept 
than with ciclosporin did not translate into a significantly lower risk of death-censored graft 
failure at 7 years of follow-up1. Validation of these potential markers is, therefore, still 
required.  
 
Despite the repeated efforts of the kidney transplant community to achieve endorsement of 
surrogate markers for conditional (EMA) or accelerated (FDA) drug approval, no individual or 
composite marker has been sufficiently validated in kidney transplant recipients who are not 
at increased risk of graft failure. Moreover, rapid validation of surrogate end points in low-
risk kidney transplant recipients is not anticipated because of the lack of new long-term 
studies using innovator drugs, heterogeneity in the causes of graft failure, the low risk of 
ABMR, and the non-specificity of many suggested markers (including GFR, chronic 
histological injury, inflammation and proteinuria) for specific disease processes. 
 
Thus the question that emerges is whether health authorities will allow conditional or 
accelerated marketing authorization for therapies in low-risk kidney transplant recipients 
without thorough validation of putative surrogate end points. In the meantime, the design 
of the BENEFIT study (noninferiority with broad margins for classic end points and 
superiority for GFR), is the most effective approach to enable new therapies for kidney 
transplantation, notwithstanding the inherent assumptions and interpretative difficulties 
that are associated with the use of a noninferiority design10. 
 
The BENEFIT study1 represents an optimistic signal to the clinical transplant community, to 
academia, to the pharmaceutical industry and to patients, that hope still exists for a brighter 
future after kidney transplantation. The noninferiority design and the virtual abandoning of 
unspecified acute rejection as primary end point (by choosing large noninferiority margins) 
show a feasible trajectory to further development of other innovator drugs that aim to 
improve long-term outcomes. 
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Pullquotes: 
... unspecified acute rejection should no longer be considered the primary end point... 
...hope still exists for a brighter future after kidney transplantation... 
 
Table 1 | Data used for the approval of immunosuppressive drugs in kidney transplantation 
 
Drug  Year of first 
approval* 
Study regimen Study design(s) Primary outcome or 
definition of efficacy 
failure  
Graft 
survival 
Patient 
survival 
Death-censored 
graft survival 
Acute 
rejection 
Graft 
function 
Azathioprine 1968 Azathioprine & high-dose 
CS 
Case series Graft loss or death NA NA NA NA NA 
Ciclosporin 1983 Ciclosporin & low-dose CS Randomized 
superiority trials 
Graft loss or death ↑ ↑ ↑ ↓ ↓ 
Mycophenolate mofetil 1995 Mycophenolate mofetil, 
ciclosporin & CS ± ATG 
Randomized 
superiority trials 
Composite of BPAR, 
graft loss, death or 
discontinuation 
= = = ↓ ↑ 
Daclizumab 1997 Daclizumab, ciclosporin & 
CS ± AZA 
Randomized 
superiority trials 
BPAR by 6 months = = = ↓ ↑ 
Tacrolimus 1997 Tacrolimus, azathioprine, 
CS & ALG  
Randomized 
superiority trials 
Composite of BPAR, 
graft loss, death or 
discontinuation 
= = = ↓ = 
Basiliximab 1998 Basiliximab, ciclosporin & 
CS 
Randomized 
superiority trials 
BPAR by 6 months = = = ↓ = 
Sirolimus 1999 Sirolimus, ciclosporin & 
steroids 
Randomized 
superiority trials 
Composite of BPAR, 
graft loss, death or loss 
to follow-up 
= = = ↓ ↓ 
Everolimus 2003 Everolimus, ciclosporin & 
basiliximab ± CS 
Randomized 
equivalence trial 
Composite of BPAR, 
graft loss, death or loss 
to follow-up 
= = = = ↓ 
Belatacept 2011 Belatacept, mycophenolate 
mofetil, CS & basiliximab 
Randomized 
noninferiority trial 
Noninferiority for BPAR, 
graft loss and death; 
superiority for GFR 
∕
‡
 ∕
‡
 = ↑ ↑ 
*FDA or EMA approval. ‡No difference at 1 year or 3 years after transplantation, but 
significant improvement with belatacept versus ciclosporin at 7 year follow-up1. ATG and 
ALG are not included in this table as these therapies are considered to be biologics so are 
not subject to the same FDA and EMA regulations as the listed drugs. ALG, antilymphocyte 
globulin; ATG, antithymocyte globulin; BPAR, biopsy-proven acute rejection; CS, 
glucocorticoids or other corticosteroids; GFR, glomerular filtration rate; NA, not applicable. 
